Figure 5.

The analysis of anti-tumor immune responses induced by Il2/ZIF-8@Salmonella in murine melanoma model. (A) The representative IHC results showing the F4/80 in melanomas treated with indicated regimes. Scale bars = 50 μm. (B) The representative IHC results showing the CD8α in melanomas treated with indicated regimes. Scale bars = 50 μm. (C) Representative images for the flow cytometry analysis of CD206 and iNOS expression in CD45⁺F4/80⁺ cells in melanomas. (D) Representative images for the flow cytometry analysis of CD8α and CD69 expression in CD45⁺CD3⁺ intratumoral lymphocytes. (E) The histogram showing the percentage of iNOS⁺CD206^- in F4/80⁺ cells in melanomas treated with indicated regimes. n = 3. Data were expressed as mean ± SD. Student’ t test was carried out using PBS-treated group as control for each treatment regime. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ns, not significant. (F) The histogram showing the percentage of CD206⁺ iNOS-in F4/80⁺ cells in melanomas treated with indicated regimes. n = 3. Data were expressed as mean ± SD. Students' t test was carried out using PBS-treated group as control for each treatment regime. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ns, not significant. (G) The histogram showing the percentage of CD8α⁺ in CD3⁺ lymphocytes in melanomas treated with indicated regimes. n = 3. Data were expressed as mean ± SD. Students' t test was carried out using PBS-treated group as control for each treatment regime. ∗∗∗P < 0.001; ns, not significant. (H) The histogram showing the percentage of CD8α⁺CD69⁺ in CD3⁺ lymphocytes in melanomas treated with indicated regimes. n = 3. Data were expressed as mean ± SD. Students' t test was carried out using PBS-treated group as control for each treatment regime. ∗∗∗P < 0.001; ns, not significant.